Xenon reports 2024 net loss $234.3M; CFO resigns; Phase 3 azetukalner FOS data due H2 2025

Xenon Pharmaceuticals Inc.

Net loss for 2024 was $234.3M ($65.7M Q4), vs $182.4M in 2023; R&D spend rose to $210.4M.
Cash and marketable securities $754.4M as of Dec 31, 2024; sufficient to fund operations into 2027.
Phase 3 X-TOLE2/3 azetukalner FOS topline data expected H2 2025; Phase 3 MDD and bipolar depression trials advancing.
CFO Sherry Aulin resigns effective June 30, 2025, for personal reasons; will advise through Aug 31, 2025.
Neurocrine collaboration milestone triggers $7.5M payment; Phase 1 study of Nav1.2/1.6 inhibitor initiated.

item 2.02 item 5.02 item 7.01 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

Sherry Aulin

Chief Financial Officer

XENE · Xenon Pharmaceuticals Inc.

Effective: 2025-06-30
Filed: February 27, 2025, 6:59 PM ET

On February 24, 2025, Ms. Sherry Aulin notified the Company of her decision to resign as Chief Financial Officer, effective June 30, 2025, for personal reasons.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 1.0

Sherry Aulin resigned as Chief Financial Officer at Xenon Pharmaceuticals Inc..

Action: resigned
Role: Chief Financial Officer

Exact text from the filing

On February 24, 2025, Ms. Sherry Aulin notified the Company of her decision to resign as Chief Financial Officer, effective June 30, 2025, for personal reasons.

View on SEC.gov

Xenon Pharmaceuticals Inc. filing history →

Source: SEC EDGAR

accession 0000950170-25-029010

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.